|
1
|
Keating MJ, Chiorazzi N, Messmer B, Damle
RN, Allen SL;, Rai KR, Ferrarini M and Kipps TJ: Biology and
treatment of chronic lymphocytic leukemia. Hematology Am Soc
Hematol Educ Program. 2003:153–175. 2003. View Article : Google Scholar
|
|
2
|
Tam CS and Keating MJ: Chemoimmunotherapy
of chronic lymphocytic leukemia. Best Pract Res Clin Haematol.
20:479–498. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chiorazzi N, Rai KR and Ferrarini M:
Chronic lymphocytic leukemia. N Engl J Med. 352:804–815. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Munk Pedersen I and Reed J:
Microenvironmental interactions and survival of CLL B-cells. Leuk
Lymphoma. 45:2365–2372. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Silber R, Farber CM, Papadopoulos E,
Nevrla D, Liebes L, Bruck M, Brown R and Canellakis ZN: Glutathione
depletion in chronic lymphocytic leukemia B lymphocytes. Blood.
80:2038–2043. 1992.PubMed/NCBI
|
|
6
|
Collins RJ, Verschuer LA, Harmon BV,
Prentice RL, Pope JH and Kerr JF: Spontaneous programmed death
(apoptosis) of B-chronic lymphocytic leukaemia cells following
their culture in vitro. Br J Haematol. 71:343–350. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou Y, Hileman EO, Plunkett W, Keating MJ
and Huang P: Free radical stress in chronic lymphocytic leukemia
cells and its role in cellular sensitivity to ROS-generating
anticancer agents. Blood. 101:4098–4104. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang W, Trachootham D, Liu J, Chen G,
Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W,
Keating MJ and Huang P: Stromal control of cystine metabolism
promotes cancer cell survival in chronic lymphocytic leukaemia. Nat
Cell Biol. 14:276–286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu WS, Parmigiani RB and Marks PA: Histone
deacetylase inhibitors: Molecular mechanisms of action. Oncogene.
26:5541–5552. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rosato RR, Almenara JA and Grant S: The
histone deacetylase inhibitor MS-275 promotes differentiation or
apoptosis in human leukemia cells through a process regulated by
generation of reactive oxygen species and induction of p21CIP1/WAF1
1. Cancer Res. 63:3637–3645. 2003.PubMed/NCBI
|
|
12
|
Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y,
Yang H, Zhang W, Fiskus W, Bhalla K, et al: Overcoming resistance
to histone deacetylase inhibitors in human leukemia with the redox
modulating compound β-phenylethyl isothiocyanate. Blood.
116:2732–2741. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
O'Connor OA, Heaney ML, Schwartz L,
Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C,
Portlock C, Horwitz S, et al: Clinical experience with intravenous
and oral formulations of the novel histone deacetylase inhibitor
suberoylanilide hydroxamic acid in patients with advanced
hematologic malignancies. J Clin Oncol. 24:166–173. 2006.
View Article : Google Scholar
|
|
14
|
Stamatopoulos B, Meuleman N, De Bruyn C,
Delforge A, Bron D and Lagneaux L: The histone deacetylase
inhibitor suberoylanilide hydroxamic acid induces apoptosis,
downregulates the CXCR4 chemokine receptor and impairs migration of
chronic lymphocytic leukemia cells. Haematologica. 95:1136–1143.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pérez-Perarnau A, Coll-Mulet L,
Rubio-Patiño C, Iglesias-Serret D, Cosialls AM, González-Gironès
DM, de Frias M, de Sevilla AF, de la Banda E, Pons G and Gil J:
Analysis of apoptosis regulatory genes altered by histone
deacetylase inhibitors in chronic lymphocytic leukemia cells.
Epigenetics. 6:1228–1235. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Abou-Nassar K and Brown JR: Novel agents
for the treatment of chronic lymphocytic leukemia. Clin Adv Hematol
Oncol. 8:886–895. PubMed/NCBI
|
|
17
|
Blum KA, Advani A, Fernandez L, Van Der
Jagt R, Brandwein J, Kambhampati S, Kassis J, Davis M, Bonfils C,
Dubay M, et al: Phase II study of the histone deacetylase inhibitor
MGCD0103 in patients with previously treated chronic lymphocytic
leukaemia. Br J Haematol. 147:507–514. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Byrd JC, Marcucci G, Parthun MR, Xiao JJ,
Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, et al: A
phase 1 and pharmacodynamic study of depsipeptide (FK228) in
chronic lymphocytic leukemia and acute myeloid leukemia. Blood.
105:959–967. 2005. View Article : Google Scholar
|
|
19
|
Cheson BD, Bennett JM, Grever M, Kay N,
Keating MJ, O'Brien S and Rai KR: National cancer
institute-sponsored working group guidelines for chronic
lymphocytic leukemia: revised guidelines for diagnosis and
treatment. Blood. 87:4990–4997. 1996.PubMed/NCBI
|
|
20
|
Huang P, Sandoval A, Van Den Neste E,
Keating MJ and Plunkett W: Inhibition of RNA transcription: A
biochemical mechanism of action against chronic lymphocytic
leukemia cells by fludarabine. Leukemia. 14:1405–1413. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Iverson SL and Orrenius S: The
cardiolipincytochrome c interaction and the mitochondrial
regulation of apoptosis. Arch Biochem Biophys. 423:37–46. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zenkov NK, Menshchikova EB and Tkachev VO:
Keap1/Nrf2/ARE redox-sensitive signaling system as a
pharmacological target. Biochemistry (Mosc). 78:19–36. 2013.
View Article : Google Scholar
|
|
23
|
Trachootham D, Zhang H, Zhang W, Feng L,
Du M, Zhou Y, Chen Z, Pelicano H, Plunkett W, Wierda WG, et al:
Effective elimination of fludarabine-resistant CLL cells by PEITC
through a redox-mediated mechanism. Blood. 112:1912–1922. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pelicano H, Xu RH, Du M, Feng L, Sasaki R,
Carew JS, Hu Y, Ramdas L, Hu L, Keating MJ, et al: Mitochondrial
respiration defects in cancer cells cause activation of Akt
survival pathway through a redox-mediated mechanism. J Cell Biol.
175:913–923. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ungerstedt JS, Sowa Y, Xu WS, Shao Y,
Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X and Marks PA:
Role of thioredoxin in the response of normal and transformed cells
to histone deacetylase inhibitors. Proc Natl Acad Sci USA.
102:673–678. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Itoh K, Wakabayashi N, Katoh Y, Ishii T,
Igarashi K, Engel JD and Yamamoto M: Keap1 represses nuclear
activation of antioxidant responsive elements by Nrf2 through
binding to the amino-terminal Neh2 domain. Genes Dev. 13:76–86.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dinkova-Kostova AT, Holtzclaw WD, Cole RN,
Itoh K, Wakabayashi N, Katoh Y, Yamamoto M and Talalay P: Direct
evidence that sulfhydryl groups of Keap1 are the sensors regulating
induction of phase 2 enzymes that protect against carcinogens and
oxidants. Proc Natl Acad Sci USA. 99:11908–11913. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu SC: Regulation of glutathione
synthesis. Curr Top Cell Regul. 36:95–116. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Craig RW: MCL1 provides a window on the
role of the BCL2 family in cell proliferation, differentiation and
tumorigenesis. Leukemia. 16:444–454. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Balakrishnan K, Burger JA, Wierda WG and
Gandhi V: AT-101 induces apoptosis in CLL B cells and overcomes
stromal cell-mediated Mcl-1 induction and drug resistance. Blood.
113:149–153. 2009. View Article : Google Scholar :
|
|
31
|
Zenz T, Häbe S, Denzel T, Mohr J, Winkler
D, Bühler A, Sarno A, Groner S, Mertens D, Busch R, et al: Detailed
analysis of p53 pathway defects in fludarabine-refractory chronic
lymphocytic leukemia (CLL): Dissecting the contribution of 17p
deletion, TP53 mutation, p53-p21 dysfunction and miR34a in a
prospective clinical trial. Blood. 114:2589–2597. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Caligaris-Cappio F: Biology of chronic
lymphocytic leukemia. Rev Clin Exp Hematol. 4:5–21. 2000.
View Article : Google Scholar
|
|
33
|
Shao Y, Gao Z, Marks PA and Jiang X:
Apoptotic and autophagic cell death induced by histone deacetylase
inhibitors. Proc Natl Acad Sci USA. 101:18030–18035. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Okabe S, Tauchi T, Kimura S, Maekawa T,
Kitahara T, Tanaka Y and Ohyashiki K: Combining the ABL1 kinase
inhibitor ponatinib and the histone deacetylase inhibitor
vorinostat: A potential treatment for BCR-ABL-positive leukemia.
PLoS One. 9:e890802014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Thurn KT, Thomas S, Moore A and Munster
PN: Rational therapeutic combinations with histone deacetylase
inhibitors for the treatment of cancer. Future Oncol. 7:263–283.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nimmanapalli R, Fuino L, Stobaugh C,
Richon V and Bhalla K: Cotreatment with the histone deacetylase
inhibitor suberoylanilide hydroxamic acid (SAHA) enhances
imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia
cells. Blood. 101:3236–3239. 2003. View Article : Google Scholar
|
|
37
|
He LZ, Tolentino T, Grayson P, Zhong S,
Warrell RP Jr, Rifkind RA, Marks PA, Richon VM and Pandolfi PP:
Histone deacetylase inhibitors induce remission in transgenic
models of therapy-resistant acute promyelocytic leukemia. J Clin
Invest. 108:1321–1330. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
VanderMolen KM, McCulloch W, Pearce CJ and
Oberlies NH: Romidepsin (Istodax, NSC 630176, FR901228, FK228,
depsipeptide): A natural product recently approved for cutaneous
T-cell lymphoma. J Antibiot (Tokyo). 64:525–531. 2011. View Article : Google Scholar
|
|
39
|
Garcia-Manero G, Yang H, Bueso-Ramos C,
Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G,
Rosner G, et al: Phase 1 study of the histone deacetylase inhibitor
vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients
with advanced leukemias and myelodysplastic syndromes. Blood.
111:1060–1066. 2008. View Article : Google Scholar
|
|
40
|
Kansanen E, Kuosmanen SM, Leinonen H and
Levonen AL: The Keap1-Nrf2 pathway: Mechanisms of activation and
dysregulation in cancer. Redox Biol. 1:45–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bannai S: Transport of cystine and
cysteine in mammalian cells. Biochim Biophys Acta. 779:289–306.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kitada S, Andersen J, Akar S, Zapata JM,
Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, et
al: Expression of apoptosis-regulating proteins in chronic
lymphocytic leukemia: Correlations with in vitro and in vivo
chemoresponses. Blood. 91:3379–3389. 1998.PubMed/NCBI
|
|
43
|
Nijhawan D, Fang M, Traer E, Zhong Q, Gao
W, Du F and Wang X: Elimination of Mcl-1 is required for the
initiation of apoptosis following ultraviolet irradiation. Genes
Dev. 17:1475–1486. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Adams KW and Cooper GM: Rapid turnover of
mcl-1 couples translation to cell survival and apoptosis. J Biol
Chem. 282:6192–6200. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Inoue S, Walewska R, Dyer MJ and Cohen GM:
Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in
leukemic cells. Leukemia. 22:819–825. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ghezzi P: Regulation of protein function
by glutathionylation. Free Radic Res. 39:573–580. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
An X, Schulz VP, Li J, Wu K, Liu J, Xue F,
Hu J, Mohandas N and Gallagher PG: Global transcriptome analyses of
human and murine terminal erythroid differentiation. Blood.
123:3466–3477. 2014. View Article : Google Scholar : PubMed/NCBI
|
